155 related articles for article (PubMed ID: 10697955)
21. Distribution of alpha-galactosidase A in normal human kidney and renal accumulation and distribution of recombinant alpha-galactosidase A in Fabry mice.
Christensen EI; Zhou Q; Sørensen SS; Rasmussen AK; Jacobsen C; Feldt-Rasmussen U; Nielsen R
J Am Soc Nephrol; 2007 Mar; 18(3):698-706. PubMed ID: 17287429
[TBL] [Abstract][Full Text] [Related]
22. Correction of the nonlinear dose response improves the viability of adenoviral vectors for gene therapy of Fabry disease.
Ziegler RJ; Li C; Cherry M; Zhu Y; Hempel D; van Rooijen N; Ioannou YA; Desnick RJ; Goldberg MA; Yew NS; Cheng SH
Hum Gene Ther; 2002 May; 13(8):935-45. PubMed ID: 12031126
[TBL] [Abstract][Full Text] [Related]
23. [Gene therapy of Gaucher's and Fabry's diseases: current status and prospects].
Fabrega S; Lehn P
J Soc Biol; 2002; 196(2):175-81. PubMed ID: 12360746
[TBL] [Abstract][Full Text] [Related]
24. The molecular defect leading to Fabry disease: structure of human alpha-galactosidase.
Garman SC; Garboczi DN
J Mol Biol; 2004 Mar; 337(2):319-35. PubMed ID: 15003450
[TBL] [Abstract][Full Text] [Related]
25. Corrective effect on Fabry mice of yeast recombinant human alpha-galactosidase with N-linked sugar chains suitable for lysosomal delivery.
Sakuraba H; Chiba Y; Kotani M; Kawashima I; Ohsawa M; Tajima Y; Takaoka Y; Jigami Y; Takahashi H; Hirai Y; Shimada T; Hashimoto Y; Ishii K; Kobayashi T; Watabe K; Fukushige T; Kanzaki T
J Hum Genet; 2006; 51(4):341-352. PubMed ID: 16532254
[TBL] [Abstract][Full Text] [Related]
26. Expression and characterization of glycosylated and catalytically active recombinant human alpha-galactosidase A produced in Pichia pastoris.
Chen Y; Jin M; Egborge T; Coppola G; Andre J; Calhoun DH
Protein Expr Purif; 2000 Dec; 20(3):472-84. PubMed ID: 11087687
[TBL] [Abstract][Full Text] [Related]
27. Retrovirus-mediated transfer of human alpha-galactosidase A gene to human CD34+ hematopoietic progenitor cells.
Takiyama N; Dunigan JT; Vallor MJ; Kase R; Sakuraba H; Barranger JA
Hum Gene Ther; 1999 Dec; 10(18):2881-9. PubMed ID: 10609650
[TBL] [Abstract][Full Text] [Related]
28. HIV-2 derived lentiviral vectors: gene transfer in Parkinson's and Fabry disease models in vitro.
D'Costa J; Harvey-White J; Qasba P; Limaye A; Kaneski CR; Davis-Warren A; Brady RO; Bankiewicz KS; Major EO; Arya SK
J Med Virol; 2003 Oct; 71(2):173-82. PubMed ID: 12938190
[TBL] [Abstract][Full Text] [Related]
29. Fabry disease: D313Y is an alpha-galactosidase A sequence variant that causes pseudodeficient activity in plasma.
Froissart R; Guffon N; Vanier MT; Desnick RJ; Maire I
Mol Genet Metab; 2003 Nov; 80(3):307-14. PubMed ID: 14680977
[TBL] [Abstract][Full Text] [Related]
30. Gene transfer and expression of human alpha-galactosidase from mouse muscle in vitro and in vivo.
Novo FJ; Górecki DC; Goldspink G; MacDermot KD
Gene Ther; 1997 May; 4(5):488-92. PubMed ID: 9274727
[TBL] [Abstract][Full Text] [Related]
31. Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease.
Schiffmann R; Murray GJ; Treco D; Daniel P; Sellos-Moura M; Myers M; Quirk JM; Zirzow GC; Borowski M; Loveday K; Anderson T; Gillespie F; Oliver KL; Jeffries NO; Doo E; Liang TJ; Kreps C; Gunter K; Frei K; Crutchfield K; Selden RF; Brady RO
Proc Natl Acad Sci U S A; 2000 Jan; 97(1):365-70. PubMed ID: 10618424
[TBL] [Abstract][Full Text] [Related]
32. Sequencing and characterization of the porcine α-galactosidase A gene: towards the generation of a porcine model for Fabry disease.
Yoshimitsu M; Higuchi K; Fan X; Takao S; Medin JA; Tei C; Takenaka T
Mol Biol Rep; 2011 Jun; 38(5):3145-52. PubMed ID: 20131008
[TBL] [Abstract][Full Text] [Related]
33. A missense mutation, A156T, in the alpha-galactosidase A gene causes typical Fabry disease.
Konoshita T; Mutoh H; Yokoi T; Koni I; Miyamori I; Mabuchi H
Clin Nephrol; 2001 Mar; 55(3):243-7. PubMed ID: 11316246
[TBL] [Abstract][Full Text] [Related]
34. An in vitro model of Fabry disease.
Shu L; Murphy HS; Cooling L; Shayman JA
J Am Soc Nephrol; 2005 Sep; 16(9):2636-45. PubMed ID: 16033856
[TBL] [Abstract][Full Text] [Related]
35. Plasma chitotriosidase in male Fabry patients: a marker for monitoring lipid-laden macrophages and their correction by enzyme replacement therapy.
Vedder AC; Cox-Brinkman J; Hollak CE; Linthorst GE; Groener JE; Helmond MT; Scheij S; Aerts JM
Mol Genet Metab; 2006 Nov; 89(3):239-44. PubMed ID: 16765076
[TBL] [Abstract][Full Text] [Related]
36. Enzymatic and functional correction along with long-term enzyme secretion from transduced bone marrow hematopoietic stem/progenitor and stromal cells derived from patients with Fabry disease.
Takenaka T; Hendrickson CS; Tworek DM; Tudor M; Schiffmann R; Brady RO; Medin JA
Exp Hematol; 1999 Jul; 27(7):1149-59. PubMed ID: 10390190
[TBL] [Abstract][Full Text] [Related]
37. Retroviral coexpression of a multidrug resistance gene (MDR1) and human alpha-galactosidase A for gene therapy of Fabry disease.
Sugimoto Y; Aksentijevich I; Murray GJ; Brady RO; Pastan I; Gottesman MM
Hum Gene Ther; 1995 Jul; 6(7):905-15. PubMed ID: 7578409
[TBL] [Abstract][Full Text] [Related]
38. Long-term inhibition of glycosphingolipid accumulation in Fabry model mice by a single systemic injection of AAV1 vector in the neonatal period.
Ogawa K; Hirai Y; Ishizaki M; Takahashi H; Hanawa H; Fukunaga Y; Shimada T
Mol Genet Metab; 2009 Mar; 96(3):91-6. PubMed ID: 19091614
[TBL] [Abstract][Full Text] [Related]
39. Detection of alpha-galactosidase a mutations causing Fabry disease by denaturing high performance liquid chromatography.
Shabbeer J; Robinson M; Desnick RJ
Hum Mutat; 2005 Mar; 25(3):299-305. PubMed ID: 15712228
[TBL] [Abstract][Full Text] [Related]
40. Adenovirus-transduced lung as a portal for delivering alpha-galactosidase A into systemic circulation for Fabry disease.
Li C; Ziegler RJ; Cherry M; Lukason M; Desnick RJ; Yew NS; Cheng SH
Mol Ther; 2002 Jun; 5(6):745-54. PubMed ID: 12027559
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]